About ProPhase Labs Inc
Ticker
info
PRPH
Trading on
info
NASDAQ
ISIN
info
US74345W1080
Industry
info
Diagnostics & Research
Sector
info
Healthcare
CEO
info
Ted William Karkus
Headquarters
info
711 Stewart Avenue, Garden City, NY, United States, 11530
Employees
info
96
Website
info
prophaselabs.com
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19. It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
Metrics
BasicAdvanced
Market cap
info
$11.6M
P/E ratio
info
-
EPS
info
-$2.07
Dividend Yield
info
0.00%
Beta
info
-0.68
Forward P/E ratio
info
10.09
EBIDTA
info
$-25.5M
Ex dividend date
info
2022-05-24
Price & volume
Market cap
info
$11.6M
Average daily volume
info
1.3M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
10.09
PEG ratio
info
0
Trailing P/E
info
0
Price to sales
info
2.08
Price to book
info
1.99
Earnings
EPS
info
-$2.07
EPS estimate (current quarter)
info
-$0.15
EPS estimate (next quarter)
info
-$0.11
EBITDA
info
$-25.5M
Revenues (TTM)
info
$5.6M
Revenues per share (TTM)
info
$0.18
Technicals
Beta
info
-0.68
52-week High
info
$0.93
52-week Low
info
$0.22
50-day moving average
info
$0.44
200-day moving average
info
$0.38
Short ratio
info
0.61
Short %
info
3.16%
Management effectiveness
ROE (TTM)
info
-171.81%
ROA (TTM)
info
-28.85%
Profit margin
info
0.00%
Gross profit margin
info
$1.3M
Operating margin
info
-312.27%
Growth
Quarterly earnings growth (YoY)
info
-95.20%
Quarterly revenue growth (YoY)
info
-17.10%
Share stats
Outstanding Shares
info
41.5M
Float
info
38.2M
Insiders %
info
7.99%
Institutions %
info
7.01%
Analyst Insights & forecasts
info

100% Buy

0% Hold

0% Sell

Based on information from 1 analysts.

Average price target

info
$13.80
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.35
$0.04
-975.00%
Q3 • 24Missed
-$1.59
-$0.24
-562.50%
Q4 • 24Missed
-$0.13
-$0.18
26.22%
Q1 • 25Beat
-$0.11
-$0.15
26.67%
Q2 • 25Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$1.4M
$4M
277.15%
Q1 • 25
$1.2M
$-4.5M
-358.62%
Q2 • 25
-12.86%
-212.76%
-229.40%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$50.1M
$35M
69.83%
Q1 • 25
$42M
$30.6M
72.80%
Q2 • 25
-16.10%
-12.54%
4.25%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-3.4M
$0.9M
$1.9M
$-3.4M
Q1 • 25
$17.2M
$0.1M
$0.3M
$-0.8M
Q2 • 25
-608.52%
-92.15%
-86.53%
-75.04%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a ProPhase Labs Inc share?
Collapse

ProPhase Labs Inc shares are currently traded for undefined per share.

How many shares does ProPhase Labs Inc have?
Collapse

ProPhase Labs Inc currently has 41.5M shares.

Does ProPhase Labs Inc pay dividends?
Collapse

No, ProPhase Labs Inc doesn't pay dividends.

What is ProPhase Labs Inc 52 week high?
Collapse

ProPhase Labs Inc 52 week high is $0.93.

What is ProPhase Labs Inc 52 week low?
Collapse

ProPhase Labs Inc 52 week low is $0.22.

What is the 200-day moving average of ProPhase Labs Inc?
Collapse

ProPhase Labs Inc 200-day moving average is $0.38.

Who is ProPhase Labs Inc CEO?
Collapse

The CEO of ProPhase Labs Inc is Ted William Karkus.

How many employees ProPhase Labs Inc has?
Collapse

ProPhase Labs Inc has 96 employees.

What is the market cap of ProPhase Labs Inc?
Collapse

The market cap of ProPhase Labs Inc is $11.6M.

What is the P/E of ProPhase Labs Inc?
Collapse

The current P/E of ProPhase Labs Inc is null.

What is the EPS of ProPhase Labs Inc?
Collapse

The EPS of ProPhase Labs Inc is -$2.07.

What is the PEG Ratio of ProPhase Labs Inc?
Collapse

The PEG Ratio of ProPhase Labs Inc is 0.

What do analysts say about ProPhase Labs Inc?
Collapse

According to the analysts ProPhase Labs Inc is considered a buy.